Genetic and Epigenetic Tumor Suppressor Gene Silencing Are Distinct Molecular Phenotypes Driven by Growth Promoting Mutations in Nonsmall Cell Lung Cancer
Journal of Cancer Epidemiology · 2008
DOI: 10.1155/2008/215809 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Epidemiology, 2008. Verfasst von Carmen J Marsit und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Center for Environmental Health and Technology, Brown University, Providence, RI 02912, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: NIEHS NIH HHS, NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Both genetic and epigenetic alterations characterize human nonsmall cell lung cancer (NSCLC), but the biological processes that create or select these alterations remain incompletely investigated. Our hypothesis posits that a roughly reciprocal relationship between the propensity for promoter hypermethylation and a propensity for genetic deletion leads to distinct molecular phenotypes of lung cancer. To test this hypothesis, we examined promoter hypermethylation of 17 tumor suppressor genes, as a marker of epigenetic alteration propensity, and deletion events at the 3p21 region, as a marker of genetic alteration. To model the complex biology between these somatic alterations, we utilized an item response theory model. We demonstrated that tumors exhibiting LOH at greater than 30% of informative alleles in the 3p21 region have a significantly reduced propensity for hypermethylation. At the same time, tumors with activating KRAS mutations showed a significantly increased propensity for hypermethylation of the loci examined, a result similar to what has been observed in colon cancer. These data suggest that NSCLCs have distinct epigenetic or genetic alteration phenotypes acting upon tumor suppressor genes and that mutation of oncogenic growth promoting genes, such as KRAS , is associated with the epigenetic phenotype.
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Center for Environmental Health and Technology, Brown University, Providence, RI 02912, USA.
Förderung
- NIEHS NIH HHS
- NCI NIH HHS
- National Institutes of Health
- Flight Attendant Medical Research Institute
Zitieren
APA
Marsit, C. J., Houseman, E. A., Nelson, H. H., & Kelsey, K. T. (2008). Genetic and Epigenetic Tumor Suppressor Gene Silencing Are Distinct Molecular Phenotypes Driven by Growth Promoting Mutations in Nonsmall Cell Lung Cancer. Journal of Cancer Epidemiology. https://doi.org/10.1155/2008/215809
Vancouver
Marsit CJ, Houseman EA, Nelson HH, Kelsey KT. Genetic and Epigenetic Tumor Suppressor Gene Silencing Are Distinct Molecular Phenotypes Driven by Growth Promoting Mutations in Nonsmall Cell Lung Cancer. Journal of Cancer Epidemiology. 2008. doi:10.1155/2008/215809
BibTeX
@article{Marsit2008,
author = {Marsit, Carmen J and Houseman, E Andres and Nelson, Heather H and Kelsey, Karl T},
title = {Genetic and Epigenetic Tumor Suppressor Gene Silencing Are Distinct Molecular Phenotypes Driven by Growth Promoting Mutations in Nonsmall Cell Lung Cancer},
journal = {Journal of Cancer Epidemiology},
year = {2008},
doi = {10.1155/2008/215809}
}
EUVIMED